BioSquare 2010You are hereA propos de BioAlpsGalerie photosPhotos d'archivesBioSquare 2010BioSquare 2010
Find an actor
Alpine High-Tech Venture Forum 201823.10.2018The event will take place on 23 October 2018 in Lausanne
Tolerys SATherapeutics & Diagnostics, Other
Tolerys SA is an early stage biotech company developing a novel anti-inflammatory immunotherapy named EFD BCG. This product is derived from BCG vaccine using a patented inactivation process.
Therapeutics & Diagnostics, Vaccines
Preclinical studies proved that EFD BCG relies on its unique capacity to induce regulatory T cells in several models of chronic inflammatory diseases and is associated with a favorable safety profile.
In parallel to preclinical R&D, Tolerys SA has developed EFD BCG's manufacturing process and is preparing a first-in-man clinical trial.